At the forefront of lung cancer treatment皇冠注册平台

Lung cancer is the most common form of cancer worldwide, with approximately 2 million cases diagnosed and 1.8 million deaths every year.1 Only 16% of patients are diagnosed when the tumour is still localised to the lung and for those patients diagnosed at a later stage, the prognosis is especially poor.2 As such, AstraZeneca is prioritising lung cancer research to address the significant unmet need for treatments at every stage of the disease continuum. Our focus is primarily on non-small cell lung cancer (NSCLC), which accounts for 80 to 85 percent of all lung cancer cases globally.3 We also have ongoing research in small cell lung cancer (SCLC), an area of high unmet need, which makes up the remaining 15 to 20 percent of cases.3-4皇冠注册平台


AstraZeneca has a portfolio of approved and potential new medicines in late-stage clinical development for the treatment of NSCLC across all stages of disease and lines of therapy.4 Our approach is focused on using ground-breaking science to further our understanding of lung cancer by identifying biomarkers which provide actionable targets for the development of precision medicines. Biomarkers are biological molecules found in body fluids or tissues that provide insight into the state of the disease, such as gene mutations or protein expressions, and are integral to understanding its biology.5-6皇冠注册平台


AstraZeneca is focusing our lung cancer research and development efforts on discovering and targeting the genetic drivers and resistance mechanisms of cancer. By identifying the mechanisms through which tumour cells grow and proliferate, we can develop drugs that target these molecules, and this has been driving our work in NSCLC for nearly thirty years.7皇冠注册平台

Our research has led us to address the unmet needs of patients with mutations in the epidermal growth factor receptor (EGFR), which occur in 10-15% of NSCLC patients in the US and EU, and 30-40% of NSCLC patients in Asia.8-10 For those patients that we cannot serve with EGFR-targeted therapies, our extensive late-stage Immuno-Oncology programme may provide clinical benefit.4皇冠注册平台


As we're continuing to advance science for NSCLC patients with an identifiable driver mutation, we are simultaneously driving towards a new era with our lmmuno-Oncology pipeline. AstraZeneca's investigational lmmuno-Oncology therapies have been designed to target immune checkpoints that are exploited by cancer to avoid or suppress the immune system’s ability to recognise and destroy tumour cells.11皇冠注册平台


lntegral to matching patients to the right treatment at the right time, is the development of companion diagnostics. Quality of testing is paramount to treatment decision-making for optimal patient outcomes, and testing is critical at every stage of the disease continuum.12 Alongside our innovative therapies, we are collaborating to deliver a range of diagnostic technologies to assess disease at all stages and ensure development of optimally-targeted therapies.

AstraZeneca partnered to launch the first tissue-based diagnostic and the first plasma-based (ctDNA) diagnostic to identify EGFR mutations in NSCLC, both of which are used extensively in clinical practice.13-14皇冠注册平台



  • 皇冠注册平台

    Activating the body’s own immune system to help fight cancer

  • 皇冠注册平台

    Targeting the genetic mutations and resistance mechanisms that enable cancer cells to evade treatment, survive, and proliferate

  • 皇冠注册平台

    Delivering highly potent cancer-killing agents directly to cancer cells via a linker attached to a targeted antibody


Learning about Lung Cancer皇冠注册平台

Targeting Tumour Drivers and Resistance皇冠注册平台

Targeted Therapy and the Future of Lung Cancer Management皇冠注册平台


At AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. Join us and help deliver life-changing medicines. Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals. 


"I believe personalised healthcare is the future of medicine; it allows us to use the latest diagnostic science to target medicines to patients most likely to benefit." Ruth March, Senior Vice-President of Precision Medicine, R&D Oncology


1.       World Health Organization. Cancer Fact Sheet. Available at新闻-room/fact-sheets/详细/cancer. Accessed February 2020.

2.       American Lung Association. Lung Cancer Fact Sheet. Available at Accessed February 2020. 

3.       American Cancer Society. What is Lung Cancer? Available at关于/what-is.html. Accessed February 2020.

4.       AstraZeneca. Clinical Trials Appendix FY 2019 Results Update. Available at Accessed February 2020.

5.        National Cancer Institute. NCI Dictionary of Cancer Terms: Biomarker. Available at Accessed February 2020.

6.       Villalobos P, et al. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13–29.

7.       National Cancer Institute. Targeted Cancer Therapies. Available at关于-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet. Accessed February 2020.

8.       Szumera-Ciećkiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12):2800-12.

9.       Keedy VL, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29: 2121-7.

10.    Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013; 66:79-89.

11.    American Cancer Society. Immune Checkpoint Inhibitors and Their Side Effects. Available at Accessed February 2020.

12.    Mayo Clinic. Lung Cancer Diagnosis. Available at Accessed February 2020.

13.    AstraZeneca LLC. AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291. Available at!. Accessed February 2020.

14.    Siravegna G, et al. How Liquid Biopsies Can Change Clinical Practice in Oncology. Annals of Oncology. 2019;30:1580-1590.


Document ID: Z4-24417
Date of prep: May 2020